Vaxcyte (PCVX) is back in focus after the company reported a first quarter net loss of US$320.62 million, along with updates on its advancing VAX-31 vaccine trials and an upcoming study for VAX-A1.

The stock has given up some ground recently, with a 1 day share price return of 9.84% decline and a 30 day share price return of 15.18% decline. However, the year to date share price return is 10.8% and the 1 year total shareholder return is 63.69%, suggesting momentum has cooled in the short term despite a stronger longer term record.

If Vaxcyte’s recent swings have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning 35 healthcare AI stocks

With Vaxcyte still loss making but carrying a market cap of about US$8.24b and trading at a sizeable discount to one estimate of intrinsic value, you have to ask: is there a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 52.8% Undervalued

With Vaxcyte last closing at $51.48 against a narrative fair value of $109, the valuation hinges on how its late stage vaccine pipeline turns into future revenue.

Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.

Want to see what kind of revenue ramp and margin profile are baked into that fair value? The narrative leans on rapid top line growth, improving profitability and a punchy future earnings multiple that is usually reserved for market favorites.

Result: Fair Value of $109 (UNDERVALUED)

However, this hinges on clinical success and smooth manufacturing, and setbacks on key VAX-31 data or cost overruns at new facilities could quickly challenge that undervalued story.

Next Steps

If this mix of risks and rewards feels finely balanced, take advantage of the current information and form your own view by weighing up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Vaxcyte is already on your radar, do not stop there. A wider watchlist can help you spot opportunities you might otherwise miss.

• Hunt for potential value opportunities by scanning companies that currently look mispriced using the 51 high quality undervalued stocks.
• Prioritise financial strength by focusing on businesses highlighted in the solid balance sheet and fundamentals stocks screener (44 results).
• Seek lesser known opportunities by checking the screener containing 23 high quality undiscovered gems before they gain wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.